ALISO VIEJO, Calif., June 18, 2007 (PRIME NEWSWIRE) -- SenoRx, Inc. (Nasdaq:SENO) today announced that the United States Patent and Trademark Office has granted the company its third patent related to its recently cleared Multi-Lumen Radiation Balloon Applicator for the treatment of breast cancer. The new claims allowed in this patent strengthen the current intellectual property for certain proprietary manufacturing and product design aspects of the Radiation Balloon.
SenoRx received 510(k) clearance from the U.S. Food and Drug Administration to market the Radiation Balloon for brachytherapy on May 23, 2007. The company expects to sell the Radiation Balloon for post-FDA clearance human clinical trials supporting marketing claims and to also host clinical education events in the second half of 2007. Full launch of the Radiation Balloon product is expected in early 2008.
SenoRx now has 46 issued United States patents primarily covering devices relating to breast biopsy, including biopsy site marking devices, excision devices and radiation balloon products.
About SenoRx
SenoRx (Nasdaq:SENO), which completed its initial public offering of common stock in March 2007, develops, manufactures and sells minimally invasive medical devices used by breast care specialists for the diagnosis of breast cancer. SenoRx's field sales organization serves over 1,000 breast diagnostic and treatment centers in the United States and Canada. With 17 products that have already received FDA 510(k) clearance across the continuum of breast care, SenoRx is developing additional minimally invasive products for diagnosis and treatment of breast cancer. For more information, visit the company's website at www.senorx.com.
The SenoRx, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3605
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning SenoRx's ability to successfully expand the balloon market, offering a solution for patients that are not otherwise candidates for balloon therapy, as well as statements about the timing of full commercial launch of the Multi-Lumen Radiation Balloon, are forward-looking statements within the meaning of the Safe Harbor. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause SenoRx's actual results to differ materially from the statements contained herein. Further information on potential risk factors that could affect SenoRx's business and its financial results are detailed in its quarterly report on Form 10-Q as filed with the Securities and Exchange Commission on May 15, 2007. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. SenoRx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.